

SAR Market 2020 Global Analysis, Share, Trend, Key Players, Opportunities & Forecast To 2025

PUNE, MAHARASTRA, INDIA, March 18, 2020 /EINPresswire.com/ -- Increasing prevalence of soft tissue sarcoma, rising Research and Development activities on drugs and other therapies, are some of the growth factors boosting the growth of the market. Soft tissue sarcoma is a type of cancer that grows from tissues such as nerves, muscles, fats, blood vessels, and thick skin tissues.

There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, Kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. There are several drugs used for the treatment of soft tissue sarcomas such as sunitinib (Sutent), trabectedin (yondelis), sirolimus (Rapamune), bevacizumab (Avastin), doxorubicin (adriamycin), and others.

@Get Free Sample Report at <https://www.wiseguyreports.com/sample-request/3792131-global-sar-market-2018-2025>

WHAT ARE THE CRITICAL APPLICATION SEGMENTS OF SOFT TISSUE SARCOMA MARKET?

In Oct 2016, U.S. Food and Drug Administration approved Eli Lilly and Company's drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types of soft tissue carcinoma.

Clinical Trial Analysis:

Total Soft Tissue Sarcoma Studies: 1567

By Disease Type, the market is segmented into Local sarcoma, Regional sarcoma, and Metastatic sarcoma. By treatment type, the soft tissue sarcoma market is segmented into radiation therapy, targeted therapy, chemotherapy, anti-angiogenesis drugs, and Others.

Chemotherapy has the largest market share in the soft tissue sarcoma market. Further, by End-user, the market has been segmented into hospitals, oncology centers, and Others. Hospitals are dominating the global soft tissue sarcoma market during the forecast period due to increasing number of patients getting treatment at hospitals for soft tissue sarcoma and other relevant cancers.

Regional Insights:

Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is leading the global soft tissue sarcoma market due to the high prevalence of cancer and soft tissue sarcoma. According to the American Cancer Society, there were more than 11,500 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. Asia-Pacific region is also growing due to rising awareness about increasing advanced treatments for cancer.

The major players of global Soft Tissue Sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Genentech), Johnson & Johnson Services, Teva Pharmaceutical Industries Ltd Celgene Corporation, and others.

Some recently approved drugs for the treatment of Soft Tissue Sarcoma are:

In June 2018, Taiwan Liposome Company, (TLC), a clinical-stage specialty pharmaceutical company declared the submission of an Investigational New Drug (IND) application with the U. S. FDA to initiate a Phase I/II, open-label, dose-escalation clinical trial of TLC178, a NanoX liposomal formulation of the anticancer drug vinorelbine, in pediatric rhabdomyosarcoma (a type of soft

tissue sarcoma) patients.

The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.

Target Audience

Raw Material Suppliers/ Buyers

Product Suppliers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Why purchase the report?

Visualize the composition of the Global Soft Tissue Sarcoma market across each indication, regarding type and applications, highlighting the critical commercial assets and players.

Identify commercial opportunities in Global Soft Tissue Sarcoma by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of the Global Soft Tissue Sarcoma market – level 4/5 segmentation

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study

Product mapping in excel for the critical Global Soft Tissue Sarcoma products of all major market players

@Enquiry Before Buying <https://www.wiseguyreports.com/enquiry/3792131-global-sar-market-2018-2025>

Table of Contents

Chapter 1. Methodology and Scope

1.1 Research methodology

1.2 Scope of the Report

Chapter 2. Executive Summary

Chapter 3. Industry Analysis

3.1 Market Drivers

3.2 Market Restraints

3.3 Porters Five Forces Analysis

3.3.1 Suppliers Power

3.3.2 Buyer Power

3.3.3 Industry Competition

3.3.4 Threat of new Entrant

3.3.5 Threat of Substitutes

Chapter 4. Global Soft Tissue Sarcoma Market □ Epidemiology

Chapter 5. Global Soft Tissue Sarcoma Market -Product Pipeline Analysis

Chapter 6. Global Soft Tissue Sarcoma Market -Clinical Trail Analysis

Chapter 7. Segmentation by Disease Type

7.1 Local sarcoma

- 7.2 Regional sarcoma
- 7.3 Metastatic sarcoma

Chapter 8. Segmentation by Treatment

- 8.1 Radiation Therapy
- 8.2 Chemotherapy
- 8.3 Targeted therapy
- 8.4 Anti-angiogenesis drugs
- 8.5 Other Treatments

Chapter 9. Segmentation by End-User

- 8.1 Hospitals
- 8.2 Oncology Centers
- 8.3 Others

Chapter 10. Geographical Analysis

- 10.1 North America
 - 10.1.1 United States
 - 10.1.2 Canada
 - 10.1.3 Mexico
 - 10.1.4 Others
- 10.2 Europe
 - 10.2.1 United Kingdom
 - 10.2.2 Spain
 - 10.2.3 Germany
 - 10.2.4 France
 - 10.2.5 Rest of Europe
- 10.3 Asia-Pacific
 - 10.3.1 India
 - 10.3.2 China
 - 10.3.3 Australia
 - 10.3.4 Japan
 - 10.3.5 Rest of Asia-Pacific
- 10.4 South America
 - 10.4.1 Brazil
 - 10.4.2 Argentina
 - 10.4.3 Rest of South America
- 10.5 Rest of the World

Chapter 11. Competitive Landscape

- 11.1 Market Share Analysis
- 11.2 Company Benchmarking
- 11.3 Key Strategies Adopted by Major Companies

Chapter 12 Company Profiles*

- 12.1 F. Hoffmann-La Roche Ltd.
- 12.2 GlaxoSmithKline Plc
- 12.3 Pfizer, Inc.
- 12.4 Johnson & Johnson Services, Inc.
- 12.5 Teva Pharmaceutical Industries Ltd.
- 12.6 Celgene Corporation

12.7 Bristol-Myers Squibb Company
12.8 Threshold Pharmaceuticals Inc.
12.9 Merck KGaA.

Chapter 12 Appendix

12.1 Sources
12.2 List of Tables
12.3 Expert Panel Validation
12.4 Disclaimer
12.5 Contact Us

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
+1 646-845-9349
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.